Tekmira and National Cancer Institute Present at AACR Annual Meeting

 Tekmira Pharmaceuticals Corporation (NASDAQ:TKMR, TSX:TKM) announced today that the company presented the encouraging results from their Phase I TKM-PLK1 clinical trial, showing selective killing of cancer cells at the annual meeting of the American Association for Cancer Research (AACR). Tekmira’s Collaboration Partner, the National Cancer Institute, is scheduled to present pre-clinical data at the same event.

The press release quotes Dr. Mark J. Murray, Tekmira’s President and CEO saying:

In addition to the encouraging results from our Phase I TKM-PLK1 clinical trial that were presented yesterday at AACR, our collaborators at the NCI have identified the novel cancer genes WEE1 and CSN5 from human tumor samples.

Click here to read the Tekmira Pharmaceuticals Corporation press release

Click here to see the Tekmira profile